United States - English - NLM (National Library of Medicine)

haemonetics corporation - citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl), trisodium citrate dihydrate (unii: b22547b95k) (anhydrous citric acid - unii:xf417d3psl), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr), anhydrous dextrose (unii: 5sl0g7r0ok) (anhydrous dextrose - unii:5sl0g7r0ok) - anhydrous citric acid 32.7 mg in 1 ml - for use with haemonetics apheresis devices rx only the haemonetics 250ml anticoagulant citrate phosphate double dextrose (cp2d) and 250ml additive solution formula 3 (as-3) nutrient solution are intended to be used only with automated apheresis devices for collecting human blood and blood components. the anticoagulant solution is metered by the apheresis machine into the collected whole blood. it is not to be infused directly into the donor. after the anticoagulant is used, the bag in which it was contained is discarded. when collecting plasma in the rbcp protocol, the plasma is collected into an empty plasma collection bag. one hundred milliliters (100ml) of as-3 is transferred into one rbc collection bag when using the rbcp protocol or 2 separate bags when using the

United States - English - NLM (National Library of Medicine)

haemonetics corporation - citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698, sodium cation - unii:lyr4m0nh37), adenine (unii: jac85a2161) (adenine - unii:jac85a2161), anhydrous dextrose (unii: 5sl0g7r0ok) (anhydrous dextrose - unii:5sl0g7r0ok), trisodium citrate dihydrate (unii: b22547b95k) (anhydrous citric acid - unii:xf417d3psl) - anhydrous citric acid 4.2 mg in 1 ml

United States - English - NLM (National Library of Medicine)

haemonetics corporation - citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), adenine (unii: jac85a2161) (adenine - unii:jac85a2161), anhydrous dextrose (unii: 5sl0g7r0ok) (anhydrous dextrose - unii:5sl0g7r0ok), trisodium citrate dihydrate (unii: b22547b95k) (anhydrous citric acid - unii:xf417d3psl) - anhydrous citric acid 4.2 mg in 1 ml - the haemonetics 250ml anticoagulant citrate phosphate double dextrose (cp2d) and 250ml additive solution formula 3 (as-3) nutrient solution are intended to be used only with automated apheresis devices for collecting human blood and blood components. the anticoagulant solution is metered by the apheresis machine into the collected whole blood. it is not to be infused directly into the donor. after the anticoagulant is used, the bag in which it was contained is discarded. when collecting plasma in the rbcp protocol, the plasma is collected into an empty plasma collection bag. one hundred milliliters (100ml) of as-3 is transferred into one rbc collection bag when using the rbcp protocol or 2 separate bags when using the 2rbc protocol. as-3 solution provides nutrients to keep the red blood cells viable for 42 days when refrigerated. cp2d is also indicated for the collection of ffp and pf24 plasma, collected and stored plasma collected using the 822, 822-2p and 822f-2p disposable sets may be frozen within 8 hours

United States - English - NLM (National Library of Medicine)

virtus pharmaceuticals llc - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 3.3 g

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 10 meq - potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)] . potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)] . potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)] . urocit ® -k is contraindicated: - in patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). - in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those sufferi

United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium picosulfate 10 mg in 16.1 g - prepopik® is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. prepopik is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute) which may result in accumulation of magnesium [see warnings and precautions (5.4)] - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)] - bowel perforation [see warnings and precautions (5.6)] - toxic colitis or toxic megacolon - gastric retention - hypersensitivity to any of the ingredients in prepopik [see adverse reactions (6.2)] risk summary there are no data with prepopik use in pregnant women to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in an animal reproduction study, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1

United States - English - NLM (National Library of Medicine)

mission pharmacal company - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 5 meq - 1.1 renal tubular acidosis (rta) with calcium stones potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)]. 1.2 hypocitraturic calcium oxalate nephrolithiasis of any etiology potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)]. 1.3 uric acid lithiasis with or without calcium stones potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)]. urocit ® -k is contraindicated: - in patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). - in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. - in patients with peptic ulcer disease because of its ulcerogenic potential. - in patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). the ability of urocit ® -k to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. moreover, the rise in urinary ph resulting from urocit ® -k therapy might promote further bacterial growth. - in patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. 8.1 pregnancy animal reproduction studies have not been conducted. it is also not known whether urocit-k can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. urocit-k should be given to a pregnant woman only if clearly needed. 8.3 nursing mothers the normal potassium ion content of human milk is about 13 meq/l. it is not known if urocit-k has an effect on this content. urocit-k should be given to a woman who is breastfeeding only if clearly needed. 8.4 pediatric use safety and effectiveness in children have not been established.

United States - English - NLM (National Library of Medicine)

cypress pharmaceutical, inc. - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl), citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 3.3 g - cytra-k crystals is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. in addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. it is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. cytra-k crystals is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. cytra-k crystals alkalinizes the urine without producing a systemic alkalosis in recommended dosage. it is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. potassium cit

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: hyprolose; calcium silicate; amaranth aluminium lake; titanium dioxide; polyvinyl acetate phthalate; diethyl phthalate; stearic acid; purified talc; povidone; hypromellose; magnesium stearate; macrogol 6000; indigo carmine aluminium lake; citric acid monohydrate - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: citric acid monohydrate; polyvinyl acetate phthalate; indigo carmine aluminium lake; hyprolose; magnesium stearate; povidone; stearic acid; amaranth aluminium lake; diethyl phthalate; purified talc; macrogol 6000; calcium silicate; hypromellose; titanium dioxide - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate.